July 27, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
A duodenal mucosal resurfacing procedure may help adults with obesity maintain weight loss 1 year after discontinuing obesity pharmacotherapy, according to topline results from the REMAIN-1 midpoint cohort. The Revita (Fractyl Health) duodenal mucosal resurfacing (DMR) system is an endoscopic procedure that remodels duodenal lining to restore healthy nutrient sensing and signaling disrupted by
July 27, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 therapy with favorable safety…

Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to a…

A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity,…

Retatrutide conferred weight loss of greater than 20% for adults with obesity and type 2 diabetes, as well as those with severe…

NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among…

Bariatric surgery may confer greater long-term weight loss than semaglutide or tirzepatide for adults with obesity, according to…